beta

ADXS

Advaxis Inc.

Adxs

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

09-10-2018 06-07-2018 03-12-2018 after market close 12-20-2017 after market close 09-11-2017 06-06-2017 03-10-2017
Actual EPS -0.27 -0.27 -0.49 -0.57 -0.8 -0.51 -0.43
Consensus EPS -0.25 -0.41 -0.58 -0.55 -0.56 -0.49 -0.52
Estimated EPS -0.25 -0.41 -0.58 -0.55 -0.56 -0.49 -0.52
Number of Estimates 2 2 2 3 2 2 2
EPS Surprise -$0.02 $0.14 $0.09 -$0.02 -$0.24 -$0.02 $0.09

Stats

Summary

Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.

Market Cap: 122 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.advaxis.com

Shares Outstanding: 41.3 Million

Float: 37 Million

Dividend: 0.0 (0.0%)

Beta: 1.722829

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 8.24 Million

Ethical Flags

Animal testing

Longest drawdown: 888 trading days

From: 2015-06-01 To: 2018-12-07

Lowest Point:

Advaxis to Present at LD Micro Main Event

via: Business Wire at 2018-11-28 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the 11… read more...

Advaxis to Present at LD Micro Main Event

via: Business Wire at 2018-11-28 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the 11… read more...

Advaxis to Present at LD Micro Main Event

via: Business Wire at 2018-11-28 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the 11… read more...

Advaxis to Present Poster Entitled "Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy" at Society for Immunotherapy of Cancer Annual Meeting

via: Business Wire at 2018-11-06 08:00:00:000

Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercial… read more...

Advaxis to Present Poster Entitled "Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy" at Society for Immunotherapy of Cancer Annual Meeting

via: Business Wire at 2018-11-06 08:00:00:000

Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercial… read more...

Advaxis to Present Poster Entitled "Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy" at Society for Immunotherapy of Cancer Annual Meeting

via: Business Wire at 2018-11-06 08:00:00:000

Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercial… read more...

Advaxis, Revisited

via: SeekingAlpha at 2018-11-05 14:01:01:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Most of my readers will know A… read more...

Advaxis' (ADXS) CEO Ken Berlin on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-02 17:08:06:000

Advaxis Inc. (ADXS) Q3 2018 Earnings Conference Call November 1, 2018 11:00 PM ET Executives Miriam Miller LHA Investor Relations Ken Berlin President and Chief Executive Officer Andres Gutierrez Chief Medical Officer Molly Henderson Chief Fi… read more...

Advaxis' (ADXS) CEO Ken Berlin on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-02 17:08:06:000

Advaxis Inc. (ADXS) Q3 2018 Earnings Conference Call November 1, 2018 11:00 PM ET Executives Miriam Miller LHA Investor Relations Ken Berlin President and Chief Executive Officer Andres Gutierrez Chief Medical Officer Molly Henderson Chief Fi… read more...

Advaxis' (ADXS) CEO Ken Berlin on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-02 17:08:06:000

Advaxis Inc. (ADXS) Q3 2018 Earnings Conference Call November 1, 2018 11:00 PM ET Executives Miriam Miller LHA Investor Relations Ken Berlin President and Chief Executive Officer Andres Gutierrez Chief Medical Officer Molly Henderson Chief Fi… read more...

Advaxis bails on Phase 1/2 study of AXAL + Imfinzi; may tweak design of Phase 3 trial of AXAL monotherapy to accelerate data readout; shares down 6% premarket

via: SeekingAlpha at 2018-11-02 09:23:49:000

Advaxis (NASDAQ: ADXS ) updates on its clinical clinical programs. Key points: More news on: Advaxis Inc., Merck & Co Inc., AstraZeneca Group plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Advaxis bails on Phase 1/2 study of AXAL + Imfinzi; may tweak design of Phase 3 trial of AXAL monotherapy to accelerate data readout; shares down 6% premarket

via: SeekingAlpha at 2018-11-02 09:23:49:000

Advaxis (NASDAQ: ADXS ) updates on its clinical clinical programs. Key points: More news on: Advaxis Inc., Merck & Co Inc., AstraZeneca Group plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Advaxis bails on Phase 1/2 study of AXAL + Imfinzi; may tweak design of Phase 3 trial of AXAL monotherapy to accelerate data readout; shares down 6% premarket

via: SeekingAlpha at 2018-11-02 09:23:49:000

Advaxis (NASDAQ: ADXS ) updates on its clinical clinical programs. Key points: More news on: Advaxis Inc., Merck & Co Inc., AstraZeneca Group plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Advaxis Provides Update on Clinical Pipeline

via: Business Wire at 2018-11-02 08:00:00:000

Continuing its Phase 3 AIM2CERV Study Anticipates Data on ADXS-PSA, ADXS-NEO and ADXS-HOT (NSCLC) in 2019 Conference Call Today at 11:00 a.m. Eastern Time Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and c… read more...

Advaxis Provides Update on Clinical Pipeline

via: Business Wire at 2018-11-02 08:00:00:000

Continuing its Phase 3 AIM2CERV Study Anticipates Data on ADXS-PSA, ADXS-NEO and ADXS-HOT (NSCLC) in 2019 Conference Call Today at 11:00 a.m. Eastern Time Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and c… read more...

Advaxis Provides Update on Clinical Pipeline

via: Business Wire at 2018-11-02 08:00:00:000

Continuing its Phase 3 AIM2CERV Study Anticipates Data on ADXS-PSA, ADXS-NEO and ADXS-HOT (NSCLC) in 2019 Conference Call Today at 11:00 a.m. Eastern Time Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and c… read more...

Advaxis to Host Business Update Conference Call on November 2, 2018

via: Business Wire at 2018-10-26 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018. Advaxis senior management will ho… read more...

Advaxis to Host Business Update Conference Call on November 2, 2018

via: Business Wire at 2018-10-26 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018. Advaxis senior management will ho… read more...

Advaxis to Host Business Update Conference Call on November 2, 2018

via: Business Wire at 2018-10-26 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018. Advaxis senior management will ho… read more...

Advaxis to Host Business Update Conference Call on November 2, 2018

via: Business Wire at 2018-10-26 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018. Advaxis senior management will ho… read more...

Advaxis to Host Business Update Conference Call on November 2, 2018

via: Business Wire at 2018-10-26 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018. Advaxis senior management will ho… read more...

Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

via: Business Wire at 2018-09-25 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the Ca… read more...

Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

via: Business Wire at 2018-09-25 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the Ca… read more...

Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

via: Business Wire at 2018-09-25 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the Ca… read more...

Advaxis closes its public offering of common stock and warrants

via: SeekingAlpha at 2018-09-11 09:55:55:000

Advaxis(NASDAQ: ADXS ) closes its previously announced public offering of 16,666,666 shares of common stock and warrants to purchase up to 14,166,666 shares of common stock for gross proceeds of ~$20M. More news on: Advaxis Inc., Healthcare stocks news, Read more … read more...

Advaxis closes its public offering of common stock and warrants

via: SeekingAlpha at 2018-09-11 09:55:55:000

Advaxis(NASDAQ: ADXS ) closes its previously announced public offering of 16,666,666 shares of common stock and warrants to purchase up to 14,166,666 shares of common stock for gross proceeds of ~$20M. More news on: Advaxis Inc., Healthcare stocks news, Read more … read more...

Advaxis closes its public offering of common stock and warrants

via: SeekingAlpha at 2018-09-11 09:55:55:000

Advaxis(NASDAQ: ADXS ) closes its previously announced public offering of 16,666,666 shares of common stock and warrants to purchase up to 14,166,666 shares of common stock for gross proceeds of ~$20M. More news on: Advaxis Inc., Healthcare stocks news, Read more … read more...

Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-11 09:20:00:000

Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds Advaxis, Inc. (NASDAQ: ADXS) (Advaxis or the Company) announced today the closing of its previously an… read more...

Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-11 09:20:00:000

Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds Advaxis, Inc. (NASDAQ: ADXS) (Advaxis or the Company) announced today the closing of its previously an… read more...

Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-11 09:20:00:000

Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds Advaxis, Inc. (NASDAQ: ADXS) (Advaxis or the Company) announced today the closing of its previously an… read more...

Advaxis  reports Q3 results

via: SeekingAlpha at 2018-09-10 16:38:07:000

Advaxis (NASDAQ: ADXS ): Q3 GAAP EPS of -$0.27. More news on: Advaxis Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

via: Business Wire at 2018-09-10 16:30:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended July 31, 2018. Recent key … read more...

Midday Gainers / Losers (09/07/2018)

via: SeekingAlpha at 2018-09-07 12:47:23:000

Gainers: OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (09/07/2018)

via: SeekingAlpha at 2018-09-07 12:47:23:000

Gainers: OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (09/07/2018)

via: SeekingAlpha at 2018-09-07 12:47:23:000

Gainers: OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more … read more...

Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-07 09:25:00:000

Advaxis, Inc. (NASDAQ:ADXS) (Advaxis or the Company) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock is … read more...

Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-07 09:25:00:000

Advaxis, Inc. (NASDAQ:ADXS) (Advaxis or the Company) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock is … read more...

Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-07 09:25:00:000

Advaxis, Inc. (NASDAQ:ADXS) (Advaxis or the Company) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock is … read more...

Premarket Losers as of 9:05 am (9/7/2018)

via: SeekingAlpha at 2018-09-07 09:10:35:000

ADXS -30% on announcing public offering of common stock and warrants. More news on: Advaxis Inc., MER Telemanagement Solutions Ltd., Ascent Capital Group, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (9/7/2018)

via: SeekingAlpha at 2018-09-07 09:10:35:000

ADXS -30% on announcing public offering of common stock and warrants. More news on: Advaxis Inc., MER Telemanagement Solutions Ltd., Ascent Capital Group, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (9/7/2018)

via: SeekingAlpha at 2018-09-07 09:10:35:000

ADXS -30% on announcing public offering of common stock and warrants. More news on: Advaxis Inc., MER Telemanagement Solutions Ltd., Ascent Capital Group, Inc., Stocks on the move, , Read more … read more...

Advaxis, Inc. announces proposed underwritten public offering of common stock and warrants

via: SeekingAlpha at 2018-09-06 17:51:00:000

Advaxis, Inc. ( ADXS -5.9% ) announced that it intends to offer and sell in an underwritten public offering shares of its common stock. More news on: Advaxis Inc., Read more … read more...

Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

via: Business Wire at 2018-09-06 17:08:00:000

Advaxis, Inc. (Nasdaq:ADXS) (Advaxis or the Company) announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to p… read more...

Biotech Analysis Central Pharma News: MannKind's Agreement, Advaxis' Partnership, Sanofi's FDA Approval

via: SeekingAlpha at 2018-09-05 06:16:44:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. MannKind Establishes Partnership Deal For Potential Inhalation Product News: Recently, MannKind ( MNKD ) announced that it had established a collabo… read more...

Your Cancer Highlight: Advaxis Resurrects A 'Dead' Bone Cancer Program

via: SeekingAlpha at 2018-09-04 16:40:24:000

One of the core criticisms that shareholders of Advaxis ( ADXS ) have had with management of the company has been an inability to capitalize on seemingly promising clinical data, as programs using their attenuated listeria-based immunotherapy languish on the vine, unable (apparently) to gain t… read more...

Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma

via: SeekingAlpha at 2018-09-04 09:29:01:000

Advaxis(NASDAQ: ADXS ) has granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. More news on: Advaxis Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma

via: Business Wire at 2018-09-04 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development and commercialization of treatm… read more...

Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned

via: SeekingAlpha at 2018-07-31 08:29:30:000

Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharmas ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d… read more...

Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned

via: SeekingAlpha at 2018-07-31 08:29:30:000

Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharmas ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d… read more...

Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned

via: SeekingAlpha at 2018-07-31 08:29:30:000

Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharmas ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d… read more...

3 Things In Biotech, July 31: Progenics Bucks The Doubters

via: SeekingAlpha at 2018-07-31 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac… read more...

3 Things In Biotech, July 31: Progenics Bucks The Doubters

via: SeekingAlpha at 2018-07-31 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac… read more...

3 Things In Biotech, July 31: Progenics Bucks The Doubters

via: SeekingAlpha at 2018-07-31 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac… read more...

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance

via: SeekingAlpha at 2018-07-31 04:58:29:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene's Profits Reach Above Expectations For The Second-Quarter News: Recently, Celgene ( CELG ) reported profit that exceeded analysts' expectat… read more...

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance

via: SeekingAlpha at 2018-07-31 04:58:29:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene's Profits Reach Above Expectations For The Second-Quarter News: Recently, Celgene ( CELG ) reported profit that exceeded analysts' expectat… read more...

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance

via: SeekingAlpha at 2018-07-31 04:58:29:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene's Profits Reach Above Expectations For The Second-Quarter News: Recently, Celgene ( CELG ) reported profit that exceeded analysts' expectat… read more...

Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer

via: Business Wire at 2018-07-30 08:00:00:000

Selects Bladder Cancer as Third ADXS-HOT Drug Candidate to Take into the Clinic after Non-Small Cell Lung and Prostate Cancers Advances Goal to Have Five Neoantigen-Based Drug Candidates in Clinical Evaluation by 4Q 2019 Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotec… read more...

Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA

via: SeekingAlpha at 2018-07-16 03:24:32:000

Stocks in News: ADXS, ATOS FDA lifts clinical hold on Advaxis study of axalimogene filolisbac; shares up 61% premarket Discussion : Advaxis ( ADXS ) announced lifting of hold on its Phase clinical trial of axalimogene filolisbac, in combination with AstraZeneca's Imfinzi (durva… read more...

Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA

via: SeekingAlpha at 2018-07-16 03:24:32:000

Stocks in News: ADXS, ATOS FDA lifts clinical hold on Advaxis study of axalimogene filolisbac; shares up 61% premarket Discussion : Advaxis ( ADXS ) announced lifting of hold on its Phase clinical trial of axalimogene filolisbac, in combination with AstraZeneca's Imfinzi (durva… read more...

Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA

via: SeekingAlpha at 2018-07-16 03:24:32:000

Stocks in News: ADXS, ATOS FDA lifts clinical hold on Advaxis study of axalimogene filolisbac; shares up 61% premarket Discussion : Advaxis ( ADXS ) announced lifting of hold on its Phase clinical trial of axalimogene filolisbac, in combination with AstraZeneca's Imfinzi (durva… read more...

Biotech Analysis Central Pharma News: Cytodyn's Acquisition, Novartis Exits Antibotic Research, Advaxis' FDA Hold Removed

via: SeekingAlpha at 2018-07-15 13:21:27:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Cytodyn Announced It Will Acquire ProstaGene LLC. News: Recently, Cytodyn ( OTCQB:CYDY ) announced that it would acquire ProstaGene LLC. so that… read more...

3 Things In Biotech, July 14: Spiking Some Good News

via: SeekingAlpha at 2018-07-14 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Takeda sticks the landing in post-transplant myeloma Company: Takeda ( TKPYY ) Therapy: Ixazomib Disease: Mult… read more...

Midday Gainers / Losers (07/13/2018)

via: SeekingAlpha at 2018-07-13 12:37:51:000

Gainers: BIOC +73% . PIXY +55% . SNES +24% . GLMD +20% . ADXS +17% . CFMS +14% . IFRX +13% . ACHN +11% . RUBI +11% . ZGNX +11% . More news on: Biocept, Inc., ShiftPixy, SenesTech, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (07/13/2018)

via: SeekingAlpha at 2018-07-13 09:11:13:000

PIXY +42% after posting FQ3 update . More news on: ShiftPixy, Advaxis Inc., Precision Therapeutics Inc., Stocks on the move, Read more … read more...

Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

via: Business Wire at 2018-07-13 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Companys Investigational … read more...

3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope

via: SeekingAlpha at 2018-07-11 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron… read more...

3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope

via: SeekingAlpha at 2018-07-11 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron… read more...

Advaxis Provides Update on MAA Filing and ADXS-HOT Program

via: Business Wire at 2018-07-10 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a clinical update, as follows: Plans to withdraw its Conditional Marketing Authorization Application (MAA) in th… read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

via: SeekingAlpha at 2018-06-13 18:00:00:000

Analysis Focus: TTPH Tetraphase Pharma ( TTPH ) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; the… read more...

Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

via: SeekingAlpha at 2018-06-13 18:00:00:000

Analysis Focus: TTPH Tetraphase Pharma ( TTPH ) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; the… read more...

Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

via: SeekingAlpha at 2018-06-13 18:00:00:000

Analysis Focus: TTPH Tetraphase Pharma ( TTPH ) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; the… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-13 08:57:05:000

Emergent BioSolutions (NYSE: EBS ) initiated with Buy rating and $62 (15% upside) price target at Argus Research. More news on: Emergent BioSolutions Inc., Advaxis Inc., ARMO BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-13 08:57:05:000

Emergent BioSolutions (NYSE: EBS ) initiated with Buy rating and $62 (15% upside) price target at Argus Research. More news on: Emergent BioSolutions Inc., Advaxis Inc., ARMO BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-13 08:57:05:000

Emergent BioSolutions (NYSE: EBS ) initiated with Buy rating and $62 (15% upside) price target at Argus Research. More news on: Emergent BioSolutions Inc., Advaxis Inc., ARMO BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

3 Things In Biotech, June 12: MET Targeting Gets On Your Radar

via: SeekingAlpha at 2018-06-13 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 12: MET Targeting Gets On Your Radar

via: SeekingAlpha at 2018-06-13 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 12: MET Targeting Gets On Your Radar

via: SeekingAlpha at 2018-06-13 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Advaxis Makes A Bold Strategic Move, Was There A Major Logical Reason Behind It?

via: SeekingAlpha at 2018-06-11 11:50:31:000

Recently, Advaxis ( ADXS ) announced plans to restructure its organization . The reason for the restructuring is to get things back on track for the biotech so that it can capitalize on its pipeline. It intends to change a few of the programs, but I believe it's for a very good reason. That… read more...

Advaxis Makes A Bold Strategic Move, Was There A Major Logical Reason Behind It?

via: SeekingAlpha at 2018-06-11 11:50:31:000

Recently, Advaxis ( ADXS ) announced plans to restructure its organization . The reason for the restructuring is to get things back on track for the biotech so that it can capitalize on its pipeline. It intends to change a few of the programs, but I believe it's for a very good reason. That… read more...

Early-stage study of Advaxis' cancer candidate ADXS-NEO underway

via: SeekingAlpha at 2018-06-11 10:27:46:000

The first patient has been dosed in a Phase 1 clinical tria l assessing Advaxis' ( ADXS ) ADXS-NEO, a personalized immunotherapy targeting cancer neoantigens, in patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squam… read more...

Early-stage study of Advaxis' cancer candidate ADXS-NEO underway

via: SeekingAlpha at 2018-06-11 10:27:46:000

The first patient has been dosed in a Phase 1 clinical tria l assessing Advaxis' ( ADXS ) ADXS-NEO, a personalized immunotherapy targeting cancer neoantigens, in patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squam… read more...

Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

via: Business Wire at 2018-06-11 08:00:00:000

-ADXS-NEO is being evaluated in a Phase 1 clinical trial in various cancers -First patient dosed is being treated for NSCLC Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, an… read more...

Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

via: Business Wire at 2018-06-11 08:00:00:000

-ADXS-NEO is being evaluated in a Phase 1 clinical trial in various cancers -First patient dosed is being treated for NSCLC Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, an… read more...

Has A New Advaxis Awakened Out Of The Doldrums?

via: SeekingAlpha at 2018-06-08 16:38:09:000

Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti… read more...

Has A New Advaxis Awakened Out Of The Doldrums?

via: SeekingAlpha at 2018-06-08 16:38:09:000

Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti… read more...

Has A New Advaxis Awakened Out Of The Doldrums?

via: SeekingAlpha at 2018-06-08 16:38:09:000

Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti… read more...

Advaxis Inc. (ADXS) CEO Ken Berlin on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-06-07 14:56:05:000

Advaxis Inc. (ADXS) Q2 2018 Earnings Conference Call June 07, 2018 11:00 AM ET Executives Miriam Miller - LHA Investor Relations Ken Berlin - President and Chief Executive Officer Andres Gutierrez - Executive Vice President and Chief Medical Officer Robert Petit - Executive Vic… read more...

This One Study Could Radically Change The Cancer Immunotherapy Market

via: SeekingAlpha at 2018-06-07 10:22:51:000

This year's American Society of Clinical Oncology ((ASCO)) conference in Chicago was chock full of the latest in cancer research and advances, but one retrospective study in particular could help radically change the way cancer immunotherapy trials are conducted going forward. The change cou… read more...

Advaxis  beats by $0.16

via: SeekingAlpha at 2018-06-07 09:22:34:000

Advaxis (NASDAQ: ADXS ): Q2 EPS of -$0.27 beats by $0.16 . More news on: Advaxis Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

via: Business Wire at 2018-06-07 09:05:00:000

Annual cash burn will be reduced to approximately $50 million from approximately $80 million through a combination of portfolio rationalization and headcount reduction Conference call begins today at 11:00 a.m. Eastern time Advaxis, Inc. (NASDAQ: ADXS), a late-stage bio… read more...

Advaxis Appoints Molly Henderson as Chief Financial Officer

via: Business Wire at 2018-06-06 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial Officer, effective June 6, 2018. … read more...

3 Things In Biotech, June 4, 2018: A Big Collaboration In The Works For Cabo?

via: SeekingAlpha at 2018-06-05 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Mining ASCO 2018's Gold, Part 9: Let's Dive Into Prostate

via: SeekingAlpha at 2018-06-02 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

via: Business Wire at 2018-06-01 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 stu… read more...

OncoSec: Will CEO O'Connor Oversee Another Advaxis-Like Run?

via: SeekingAlpha at 2018-05-31 10:31:22:000

Preface : First, I need to define a couple of terms I utilize below and going forward: Period of acceleration Period of deceleration All biotechnology companies, good and bad, experience periods of acceleration, in which the value of the shares significantly increase, and per… read more...

Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

via: Business Wire at 2018-05-31 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7… read more...

Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

via: Business Wire at 2018-05-11 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents … read more...

Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

via: Business Wire at 2018-05-11 08:00:00:000

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents … read more...

New leadership at Advaxis

via: SeekingAlpha at 2018-04-23 12:00:08:000

Advaxis ( ADXS -1.2% ) appoints Ken Berlin as President & CEO effective today replacing interim CEO Anthony Lombardo. He joins the firm from Rosetta Genomics were he was also President & CEO. More news on: Advaxis Inc., Healthcare stocks news, Read more … read more...

New leadership at Advaxis

via: SeekingAlpha at 2018-04-23 12:00:08:000

Advaxis ( ADXS -1.2% ) appoints Ken Berlin as President & CEO effective today replacing interim CEO Anthony Lombardo. He joins the firm from Rosetta Genomics were he was also President & CEO. More news on: Advaxis Inc., Healthcare stocks news, Read more … read more...

Advaxis Announces Executive Leadership Changes

via: Business Wire at 2018-04-23 08:00:00:000

Kenneth A. Berlin appointed President, CEO and Director; Dr. Andres A. Gutierrez named Chief Medical Officer; Sara Bonstein, CFO, to depart Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunothera… read more...

Advaxis Announces Executive Leadership Changes

via: Business Wire at 2018-04-23 08:00:00:000

Kenneth A. Berlin appointed President, CEO and Director; Dr. Andres A. Gutierrez named Chief Medical Officer; Sara Bonstein, CFO, to depart Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunothera… read more...

Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

via: Business Wire at 2018-04-17 08:00:00:000

Lm platform targets common mutations in tumor driver genes Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data… read more...

Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

via: Business Wire at 2018-04-17 08:00:00:000

Lm platform targets common mutations in tumor driver genes Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data… read more...

Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

via: Business Wire at 2018-04-02 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled ADXS-PSA plus pembrolizumab (pembro… read more...

Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

via: Business Wire at 2018-04-02 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled ADXS-PSA plus pembrolizumab (pembro… read more...

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

via: Business Wire at 2018-03-26 08:00:00:000

Including Three Late-Breaking Poster Presentations Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm … read more...

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

via: Business Wire at 2018-03-26 08:00:00:000

Including Three Late-Breaking Poster Presentations Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm … read more...

The No BS Plan Report, Week 6: Are We Now Seeing Some Inflection?

via: SeekingAlpha at 2018-03-24 17:20:19:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Hello all! Welcome to another week of the No BS Plan report. And this week we're in the m… read more...

The No BS Plan Report, Week 6: Are We Now Seeing Some Inflection?

via: SeekingAlpha at 2018-03-24 17:20:19:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Hello all! Welcome to another week of the No BS Plan report. And this week we're in the m… read more...

The No BS Plan Report, Week 5: Does Sideways Movement Mean An Imminent Inflection Point?

via: SeekingAlpha at 2018-03-17 14:47:57:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Spoiler alert: Week 5 was fairly boring in terms of trading. But I don't think you should st… read more...

The No BS Plan Report, Week 5: Does Sideways Movement Mean An Imminent Inflection Point?

via: SeekingAlpha at 2018-03-17 14:47:57:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Spoiler alert: Week 5 was fairly boring in terms of trading. But I don't think you should st… read more...

Key events next week - healthcare (continued #1)

via: SeekingAlpha at 2018-03-16 10:26:29:000

Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR );Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS… read more...

Key events next week - healthcare (continued #1)

via: SeekingAlpha at 2018-03-16 10:26:29:000

Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR );Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS… read more...

3 Things In Biotech, March 13, 2018: Uncertainty Abounds!

via: SeekingAlpha at 2018-03-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote… read more...

3 Things In Biotech, March 13, 2018: Uncertainty Abounds!

via: SeekingAlpha at 2018-03-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote… read more...

After Hours Gainers / Losers (2/16/2018)

via: SeekingAlpha at 2018-02-16 17:35:23:000

Top gainers: PTX +12.6% . ALSN +2.0% . SSTK +1.7% . BLCM +1.2% . More news on: Pernix Therapeutics Holdings, Inc., Allison Transmission, Shutterstock, Stocks on the move, , Read more … read more...

After Hours Gainers / Losers (2/16/2018)

via: SeekingAlpha at 2018-02-16 17:35:23:000

Top gainers: PTX +12.6% . ALSN +2.0% . SSTK +1.7% . BLCM +1.2% . More news on: Pernix Therapeutics Holdings, Inc., Allison Transmission, Shutterstock, Stocks on the move, , Read more … read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

via: SeekingAlpha at 2018-02-15 08:01:00:000

Analysis of top Seeking Alpha coverage: Achaogen Today we will focus on Achaogen ( AKAO ), which got a slight boost after Tetraphase Pharmas ( TTPH ) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaoge… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

3 Things In Biotech You Should Learn Today: February 13, 2018

via: SeekingAlpha at 2018-02-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn… read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis Takes Its First Step Towards Regulatory Approval

via: SeekingAlpha at 2018-02-14 02:40:58:000

Advaxis ( ADXS ) announced recently that it had filed its application for approval for its lead immunotherapy product known as axalimogene filolisbac. This application was filed so that the company could gain European marketing approval to treat patients with recurrent/metastatic cervical … read more...

Advaxis files marketing application in Europe for lead candidate in second-line cervical cancer

via: SeekingAlpha at 2018-02-13 10:36:46:000

Advaxis ( ADXS +0.4% ) files an application in Europe seeking conditional approval for lead candidate axalimogene filolisbac (AF)for the treatment of adult women with recurrent/metastatic cervical cancer who progress beyond first-line treatment. More news on: Advaxis Inc., Health… read more...

Advaxis files marketing application in Europe for lead candidate in second-line cervical cancer

via: SeekingAlpha at 2018-02-13 10:36:46:000

Advaxis ( ADXS +0.4% ) files an application in Europe seeking conditional approval for lead candidate axalimogene filolisbac (AF)for the treatment of adult women with recurrent/metastatic cervical cancer who progress beyond first-line treatment. More news on: Advaxis Inc., Health… read more...

Advaxis files marketing application in Europe for lead candidate in second-line cervical cancer

via: SeekingAlpha at 2018-02-13 10:36:46:000

Advaxis ( ADXS +0.4% ) files an application in Europe seeking conditional approval for lead candidate axalimogene filolisbac (AF)for the treatment of adult women with recurrent/metastatic cervical cancer who progress beyond first-line treatment. More news on: Advaxis Inc., Health… read more...

Premarket Gainers as of 9:05 am (02/13/2018)

via: SeekingAlpha at 2018-02-13 09:24:41:000

GNC +40% on Q4 result . More news on: GNC Holdings, Inc., Catabasis Pharmaceuticals, AmerisourceBergen Corporation, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/13/2018)

via: SeekingAlpha at 2018-02-13 09:24:41:000

GNC +40% on Q4 result . More news on: GNC Holdings, Inc., Catabasis Pharmaceuticals, AmerisourceBergen Corporation, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/13/2018)

via: SeekingAlpha at 2018-02-13 09:24:41:000

GNC +40% on Q4 result . More news on: GNC Holdings, Inc., Catabasis Pharmaceuticals, AmerisourceBergen Corporation, Stocks on the move, , Read more … read more...

Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

via: Business Wire at 2018-02-13 08:30:00:000

Advaxis reaches important regulatory milestone for axalimogene filolisbac with submission of Conditional MAA to treat metastatic cervical cancer in patients who progress beyond first-line therapy The MAA submission is centered around the encouraging results from the GOG-0265 study … read more...

Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

via: Business Wire at 2018-02-13 08:30:00:000

Advaxis reaches important regulatory milestone for axalimogene filolisbac with submission of Conditional MAA to treat metastatic cervical cancer in patients who progress beyond first-line therapy The MAA submission is centered around the encouraging results from the GOG-0265 study … read more...

Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

via: Business Wire at 2018-02-13 08:30:00:000

Advaxis reaches important regulatory milestone for axalimogene filolisbac with submission of Conditional MAA to treat metastatic cervical cancer in patients who progress beyond first-line therapy The MAA submission is centered around the encouraging results from the GOG-0265 study … read more...

Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer

via: Business Wire at 2018-02-12 09:15:00:000

Peer-reviewed published article shows treatment with axalimogene filolisbac resulted in an overall 12-month survival rate of approximately 35% Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunoth… read more...

Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer

via: Business Wire at 2018-02-12 09:15:00:000

Peer-reviewed published article shows treatment with axalimogene filolisbac resulted in an overall 12-month survival rate of approximately 35% Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunoth… read more...

Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer

via: Business Wire at 2018-02-12 09:15:00:000

Peer-reviewed published article shows treatment with axalimogene filolisbac resulted in an overall 12-month survival rate of approximately 35% Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunoth… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

Data Highlighting Advaxis' Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

via: Business Wire at 2018-01-29 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Companys Listeria -based immunotherapy in combination with antibody-based imm… read more...

Data Highlighting Advaxis' Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

via: Business Wire at 2018-01-29 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Companys Listeria -based immunotherapy in combination with antibody-based imm… read more...

Data Highlighting Advaxis' Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

via: Business Wire at 2018-01-29 08:00:00:000

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Companys Listeria -based immunotherapy in combination with antibody-based imm… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 26, 2018

via: SeekingAlpha at 2018-01-27 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Biotech Forum Daily Digest For January 26th

via: SeekingAlpha at 2018-01-26 10:21:50:000

Americans will put up with anything provided it doesn't block traffic . Dan Rather It has been a big week for the biotech sector. This area of the market surged on Monday and Tuesday after two big acquisitions totaling over $20 billion were announced before the market ope… read more...

Advaxis' lead candidate axalimogene filolisbac shows positive effect in early-stage anal cancer study; shares ahead 6%

via: SeekingAlpha at 2018-01-25 11:20:19:000

Advaxis ( ADXS +5.6% ) is up on 30% higher volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing lead candidate axalimogene filolisbac (ADXS11-001), in combination with chemoradiation, in patients with high-risk, locally advanced squamous ana… read more...

Advaxis' lead candidate axalimogene filolisbac shows positive effect in early-stage anal cancer study; shares ahead 6%

via: SeekingAlpha at 2018-01-25 11:20:19:000

Advaxis ( ADXS +5.6% ) is up on 30% higher volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing lead candidate axalimogene filolisbac (ADXS11-001), in combination with chemoradiation, in patients with high-risk, locally advanced squamous ana… read more...

Advaxis' lead candidate axalimogene filolisbac shows positive effect in early-stage anal cancer study; shares ahead 6%

via: SeekingAlpha at 2018-01-25 11:20:19:000

Advaxis ( ADXS +5.6% ) is up on 30% higher volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing lead candidate axalimogene filolisbac (ADXS11-001), in combination with chemoradiation, in patients with high-risk, locally advanced squamous ana… read more...

Advaxis' lead candidate axalimogene filolisbac shows positive effect in early-stage anal cancer study; shares ahead 6%

via: SeekingAlpha at 2018-01-25 11:20:19:000

Advaxis ( ADXS +5.6% ) is up on 30% higher volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing lead candidate axalimogene filolisbac (ADXS11-001), in combination with chemoradiation, in patients with high-risk, locally advanced squamous ana… read more...

Advaxis' lead candidate axalimogene filolisbac shows positive effect in early-stage anal cancer study; shares ahead 6%

via: SeekingAlpha at 2018-01-25 11:20:19:000

Advaxis ( ADXS +5.6% ) is up on 30% higher volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing lead candidate axalimogene filolisbac (ADXS11-001), in combination with chemoradiation, in patients with high-risk, locally advanced squamous ana… read more...

Premarket Gainers as of 9:05 am (1/25/2018)

via: SeekingAlpha at 2018-01-25 09:22:09:000

LTBR +99% on anticipation of news on proposed JV. More news on: Lightbridge Corp, Summit Therapeutics, RMG Networks, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (1/25/2018)

via: SeekingAlpha at 2018-01-25 09:22:09:000

LTBR +99% on anticipation of news on proposed JV. More news on: Lightbridge Corp, Summit Therapeutics, RMG Networks, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (1/25/2018)

via: SeekingAlpha at 2018-01-25 09:22:09:000

LTBR +99% on anticipation of news on proposed JV. More news on: Lightbridge Corp, Summit Therapeutics, RMG Networks, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (1/25/2018)

via: SeekingAlpha at 2018-01-25 09:22:09:000

LTBR +99% on anticipation of news on proposed JV. More news on: Lightbridge Corp, Summit Therapeutics, RMG Networks, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (1/25/2018)

via: SeekingAlpha at 2018-01-25 09:22:09:000

LTBR +99% on anticipation of news on proposed JV. More news on: Lightbridge Corp, Summit Therapeutics, RMG Networks, Stocks on the move, Read more … read more...

Advaxis' Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

via: Business Wire at 2018-01-25 08:00:00:000

All patients who completed treatment had complete clinical response Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated s… read more...

Advaxis' Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

via: Business Wire at 2018-01-25 08:00:00:000

All patients who completed treatment had complete clinical response Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated s… read more...

Advaxis' Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

via: Business Wire at 2018-01-25 08:00:00:000

All patients who completed treatment had complete clinical response Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated s… read more...

Advaxis' Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

via: Business Wire at 2018-01-25 08:00:00:000

All patients who completed treatment had complete clinical response Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated s… read more...

Advaxis' Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

via: Business Wire at 2018-01-25 08:00:00:000

All patients who completed treatment had complete clinical response Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated s… read more...

Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering

via: SeekingAlpha at 2018-01-05 01:36:56:000

Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...

Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering

via: SeekingAlpha at 2018-01-05 01:36:56:000

Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...

Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering

via: SeekingAlpha at 2018-01-05 01:36:56:000

Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...

Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering

via: SeekingAlpha at 2018-01-05 01:36:56:000

Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...

Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering

via: SeekingAlpha at 2018-01-05 01:36:56:000

Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

via: SeekingAlpha at 2017-12-30 13:35:25:000

Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

via: SeekingAlpha at 2017-12-30 13:35:25:000

Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

via: SeekingAlpha at 2017-12-30 13:35:25:000

Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

via: SeekingAlpha at 2017-12-30 13:35:25:000

Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

via: SeekingAlpha at 2017-12-30 13:35:25:000

Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

via: SeekingAlpha at 2017-12-29 01:58:47:000

Analysis of top Seeking Alpha coverage: Heron Therapeutics Today we will be discussing one of the top performing stocks in the biotech sector this year, Heron Therapeutics ( HRTX ). After two disappointing years, HRTX is headed for gains of more than 40% for this year. Despite the rally, H… read more...

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

via: SeekingAlpha at 2017-12-29 01:58:47:000

Analysis of top Seeking Alpha coverage: Heron Therapeutics Today we will be discussing one of the top performing stocks in the biotech sector this year, Heron Therapeutics ( HRTX ). After two disappointing years, HRTX is headed for gains of more than 40% for this year. Despite the rally, H… read more...

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

via: SeekingAlpha at 2017-12-29 01:58:47:000

Analysis of top Seeking Alpha coverage: Heron Therapeutics Today we will be discussing one of the top performing stocks in the biotech sector this year, Heron Therapeutics ( HRTX ). After two disappointing years, HRTX is headed for gains of more than 40% for this year. Despite the rally, H… read more...

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

via: SeekingAlpha at 2017-12-29 01:58:47:000

Analysis of top Seeking Alpha coverage: Heron Therapeutics Today we will be discussing one of the top performing stocks in the biotech sector this year, Heron Therapeutics ( HRTX ). After two disappointing years, HRTX is headed for gains of more than 40% for this year. Despite the rally, H… read more...

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

via: SeekingAlpha at 2017-12-29 01:58:47:000

Analysis of top Seeking Alpha coverage: Heron Therapeutics Today we will be discussing one of the top performing stocks in the biotech sector this year, Heron Therapeutics ( HRTX ). After two disappointing years, HRTX is headed for gains of more than 40% for this year. Despite the rally, H… read more...

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

via: SeekingAlpha at 2017-12-26 04:23:59:000

Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

via: SeekingAlpha at 2017-12-26 04:23:59:000

Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

via: SeekingAlpha at 2017-12-26 04:23:59:000

Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

via: SeekingAlpha at 2017-12-26 04:23:59:000

Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

via: SeekingAlpha at 2017-12-26 04:23:59:000

Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...

Advaxis' (ADXS) CEO Anthony Lombardo on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-12-21 14:45:07:000

Advaxis, Inc. (ADXS) Q4 2017 Results Earnings Conference December 21, 2017 10:00 AM ET Executives Noelle Heber - Senior Director Corporate Communications Anthony Lombardo - Interim CEO Sara Bonstein - EVP and CFO Robert Petit - EVP and Chief Scientific Officer Analysts Da… read more...

Advaxis' (ADXS) CEO Anthony Lombardo on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-12-21 14:45:07:000

Advaxis, Inc. (ADXS) Q4 2017 Results Earnings Conference December 21, 2017 10:00 AM ET Executives Noelle Heber - Senior Director Corporate Communications Anthony Lombardo - Interim CEO Sara Bonstein - EVP and CFO Robert Petit - EVP and Chief Scientific Officer Analysts Da… read more...

Advaxis' (ADXS) CEO Anthony Lombardo on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-12-21 14:45:07:000

Advaxis, Inc. (ADXS) Q4 2017 Results Earnings Conference December 21, 2017 10:00 AM ET Executives Noelle Heber - Senior Director Corporate Communications Anthony Lombardo - Interim CEO Sara Bonstein - EVP and CFO Robert Petit - EVP and Chief Scientific Officer Analysts Da… read more...

Advaxis' (ADXS) CEO Anthony Lombardo on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-12-21 14:45:07:000

Advaxis, Inc. (ADXS) Q4 2017 Results Earnings Conference December 21, 2017 10:00 AM ET Executives Noelle Heber - Senior Director Corporate Communications Anthony Lombardo - Interim CEO Sara Bonstein - EVP and CFO Robert Petit - EVP and Chief Scientific Officer Analysts Da… read more...

Advaxis' (ADXS) CEO Anthony Lombardo on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-12-21 14:45:07:000

Advaxis, Inc. (ADXS) Q4 2017 Results Earnings Conference December 21, 2017 10:00 AM ET Executives Noelle Heber - Senior Director Corporate Communications Anthony Lombardo - Interim CEO Sara Bonstein - EVP and CFO Robert Petit - EVP and Chief Scientific Officer Analysts Da… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX